5-year results of a randomized comparison of XIENCE v everolimus-eluting and TAXUS paclitaxel-eluting stents: Final results from the SPIRIT III trial (Clinical Evaluation of the XIENCE v Everolimus Eluting Coronary Stent System in the Treatment of Patients with de Novo Native Coronary Artery Lesions)

JACC: Cardiovascular Interventions

Volumn 6, Issue 12, 2013, Pages 1263-1266

  Gada, Hemal ^a   Kirtane, Ajay J ^a   Newman, William ^b   Sanz, Mark ^c   Hermiller, James B ^d   Mahaffey, Kenneth W ^e   Cutlip, Donald E ^f   Sudhir, Krishnankutty ^g   Hou, Liming ^g   Koo, Kai ^g   Stone, Gregg W ^a  

^a NewYork Presbyterian Hospital   (United States)

^b WAKEMED HEALTH AND HOSPITALS   (United States)

^c St Patrick Hospital and Health Sciences Center   (United States)

^d Heart Center of Indiana   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^g ABBOTT VASCULAR   (United States)

Author keywords

coronary artery disease; drug eluting stent(s); in stent restenosis; stent thrombosis; target vessel failure

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; EVEROLIMUS; PACLITAXEL; CARDIOVASCULAR AGENT; RAPAMYCIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STENT THROMBOSIS; TARGET LESION FAILURE; TARGET VESSEL FAILURE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; KAPLAN MEIER METHOD; MORTALITY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES;

CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS; KAPLAN-MEIER ESTIMATE; MYOCARDIAL INFARCTION; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SINGLE-BLIND METHOD; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84890792687     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2013.07.009     Document Type: Article

References (5)

1. G.W. Stone, M. Midei, and W. Newman Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913
2. R.J. Applegate, M. Yaqub, and J.B. Hermiller Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial) Am J Cardiol 107 2011 833 840
3. G.W. Stone, M. Midei, and W. Newman Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial Circulation 119 2009 680 686
4. G.W. Stone, A. Rizvi, and W. Newman Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
5. E. Kedhi, K.S. Joesoef, and E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209